Introduction {#Sec1}
============

The clinical and economic burden of community-acquired pneumonia (CAP) in Europe is substantial. A review of the burden of CAP in Europe demonstrated that the incidence of CAP and hospitalisations for CAP are rising \[[@CR1]\]. The incidence of CAP was shown to be higher in men than in women and to increase with age. In addition to increasing age \[[@CR1]--[@CR3]\], several other risk factors for CAP have been established, including smoking \[[@CR2]\], immunosuppression \[[@CR3]\] and the presence of comorbid conditions \[[@CR4]--[@CR7]\]. With an ageing population in Europe, the clinical and economic burden of CAP is expected to continue to rise over time, placing increasing pressure on hospital resources and society \[[@CR1], [@CR8]--[@CR11]\].

*Streptococcus pneumoniae* is widely accepted as being the most common pathogen causing CAP. However, the frequency at which it is identified varies considerably between studies across Europe \[[@CR1], [@CR12]\]. In addition to *S. pneumoniae*, several other pathogens cause CAP, including atypical pathogens such as *Legionella pneumophila* and *Staphylococcus aureus*, and Gram-negative bacilli, including *Pseudomonas aeruginosa* \[[@CR13]--[@CR18]\].

It is important to understand the emerging role of different pathogens in the aetiology of CAP to effectively guide appropriate antibiotic management \[[@CR19]\]. Inappropriate antibiotic treatment in patients with CAP has been repeatedly linked with worse outcomes \[[@CR20]--[@CR23]\]. This literature review was conducted to generate up-to-date information on the aetiology of CAP and its antibiotic management in adults across Europe.

Methods {#Sec2}
=======

The search methodology for this literature review was the same as that described for a previous literature search and analysis \[[@CR7]\], but with additional filters for the topics of interest to this review (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Summary of the study selection procedure. (Adapted from Fig. 1 of Torres et al. \[[@CR7]\], used under the Creative Commons---Attribution-NonCommercial (CC BY-NC 3.0) license. The original can be found here: <http://thorax.bmj.com/content/68/11/1057/F1.large.jpg>). *CAP* community-acquired pneumonia. \*One study did not include the terms 'risk' or 'co-morbidity'/'comorbidity' in either the title or the abstract and, so, was not identified in the PubMed searches; however, 'risk factors' was included in the list of MeSH terms for the article

The PubMed database was searched using the following search string: pneumonia AND English AND 2005/01/01--2012/07/31 AND risk NOT clinical trial, phase I OR clinical trial, phase II OR clinical trial, phase III OR controlled clinical trial OR randomized controlled trial OR case reports OR practice guideline OR editorial OR review OR cost OR cost effectiveness OR efficacy OR immunogenicity OR economic OR nosocomial. Additional searches used the same search string, but replaced 'risk' with either 'comorbidity' or 'co-morbidity'.

Articles were included in the initial literature search \[[@CR7]\] if they reported observational studies performed in Western European countries (Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, The Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, UK) and presented data from individuals \>15 years of age on either the incidence of CAP in at-risk individuals, defined as those with underlying risk factors placing them at increased risk of CAP (as defined in \[[@CR7]\]), or risk factors for CAP. The papers identified were further screened for data on pathogens identified in patients with CAP and/or antibiotic treatment in patients with CAP. Studies that focused on nosocomial or healthcare-acquired pneumonia were excluded.

The included articles were reviewed in full and data on the study setting and methodology, characteristics of the populations studied, pathogens and antibiotic treatments were extracted. If more than one paper reported different aspects of the same study, all relevant papers were included. Where the same data were reported in more than one paper, the first paper to be published was selected for inclusion. The analysis of the included papers was descriptive and no meta-analyses of data were performed. Unless otherwise stated, all data are reported as odds ratios (ORs) (95 % confidence intervals \[CIs\]).

Results {#Sec3}
=======

Included studies {#Sec4}
----------------

As reported previously \[[@CR7]\], a total of 3,331 articles published between January 2005 and July 2012 were identified, of which 3,240 could be excluded on the basis of the title, abstract or study location. Further screening of the PubMed results and full papers identified 60 references meeting the inclusion and exclusion criteria. We summarise data from 33 of these studies that reported on the pathogens identified in patients with CAP and/or antibiotic treatment in patients with CAP. The included studies were performed in Denmark (*n* = 1), France (*n* = 3), Germany (*n* = 3), Greece (*n* = 1), Italy (*n* = 4), Spain (*n* = 20) and the UK (*n* = 1). Details of the study designs and populations are summarised in Table [1](#Tab1){ref-type="table"}.Table 1Methodology and patient demographics of the studies included in the review. (Adapted from Supplementary Table 1 of Torres et al. \[[@CR7]\], used under the Creative Commons---Attribution-NonCommercial (CC BY-NC 3.0) license. The original can be found here: <http://thorax.bmj.com/content/suppl/2013/10/15/thoraxjnl-2013-204282.DC1/thoraxjnl-2013-204282supp_tables.pdf>)CitationCountry; regionStudy methodStudy periodPopulationAge (yrs \[mean ± SD\])Definition of CAPDenmark Holm et al. 2007 \[[@CR65]\]Denmark; OdenseMulticentre, prospective, observational study9 Sept--1 Nov 2002; 6 Jan--25 April 2003Primary care patients ≥18 yrs with a diagnosis of community-acquired LRTI, *n* = 364; 48 with pneumoniaOverall, median 50 \[range 18--94\]GP diagnosis of LRTI and chest X-ray confirmedPneumonia, median 61 \[range 22--88\]France Le Moing et al. 2006 \[[@CR35]\]France; nationalMulticentre, prospective, observational cohort studyMay 1997--Dec 2001HIV patients receiving protease inhibitor therapy, *n* = 1,203; 29 hospitalised with pneumoniaMedian 36Clinical symptoms, chest X-ray confirmed and microbiological data Bénard et al. 2010 \[[@CR33]\]France; AquitaineMulticentre, prospective, cohort study2000--2007Patients with HIV, *n* = 3,336; 135 with bacterial pneumoniaMedian 39.6 \[IQR 34.5--46.0\]Chest X-ray confirmed and bacteriological identification or successful antibacterial treatment Chidiac et al. 2012 \[[@CR27]\]France; metropolitanMulticentre, prospective, observational, cohort study1 April 2006--30 June 2007Patients hospitalised with community-acquired Legionnaires' disease, *n* = 54060 \[range 17--100\]Chest X-ray confirmed and laboratory evidence of *Legionella pneumophila* infectionGermany Klapdor et al. 2012 \[[@CR41]\]Germany; national (CAPNETZ)Multicentre, prospective, observational studyJan 2002--June 2009Patients ≥18 yrs with CAP, *n* = 7,803; 4,083 \<65 yrs (2.6 % nursing home residents); 3,720 ≥65 yrs (14.4 % nursing home residents)Overall, 60.9 ± 18.5 \[range 18--101\]Clinical symptoms, chest X-ray confirmed and microbiological data\<65 yrs, median 47.0 \[IQR 20.7\]≥65 yrs, median 76.0 \[IQR 11.8\] von Baum et al. 2010 \[[@CR32]\]Germany; national (CAPNETZ)Multicentre, prospective, observational study1 June 2002--30 June 2007Patients with CAP, *n* = 5,130 (6 % nursing home residents); 67 with EB; 22 with PA; 1,833 with no definite EB/PAOverall, 60 ± 18Chest X-ray or clinical symptomsWith EB, 73 ± 15With PA, 64 ± 17No EB/PA, 58 ± 18 Kothe et al. 2008 \[[@CR23]\]Germany; national (CAPNETZ)Multicentre, prospective, observational studyMarch 2003--Oct 2005Patients with CAP, *n* = 2,647; 1,298 \<65 yrs (3.3 % nursing home residents); 1,349 ≥65 yrs (15.2 % nursing home residents)\<65 yrs, 47.2 ± 12.7Clinical symptoms, chest X-ray confirmed and microbiological data≥65 yrs, 77.1 ± 7.5Greece Kofteridis et al. 2009 \[[@CR30]\]Greece; CreteSingle-centre, retrospective, observational studyJan 1996--Dec 2002Adults hospitalised with community-acquired LRTI due to *Haemophilus influenzae n* = 45Median 68 \[range 28--86\]Clinical symptoms, chest X-ray confirmed and positive sputum culture for *H. influenzae*Italy Madeddu et al. 2008 \[[@CR36]\]Italy; northern SardiniaSingle-centre, observational, retrospective analysis of consecutive patientsJan 1999--Dec 2004HIV patients hospitalised with CAP, *n* = 76; 84 episodes38.3 ± 7.5 \[range 27--80\]Clinical symptoms, chest X-ray confirmed and microbiological data  ^a^Viegi et al. 2006 \[[@CR47]\]Italy, nationalMulticentre, prospective, observational, population-based study15 Feb 1999--14 Feb 2000Primary care patients with CAP, *n* = 699; 548 diagnosed by GP (4.7 % nursing home residents); 151 diagnosed by hospital (8.9 % nursing home residents)59.6 ± 19.5Chest X-ray and clinical symptomsPatients diagnosed in community, 57.6 ± 19.2Patients diagnosed in hospital, 66.7 ± 18.7  ^b^Manno et al. 2009 \[[@CR37]\]Italy; BresciaSingle-centre, prospective, observational, cohort studyJune 2000--Dec 2006HIV patients hospitalised with CAPCirrhosis, 41.0 ± 4.3Clinical symptoms, chest X-ray confirmed and microbiological dataPatients with cirrhosis, *n* = 29No cirrhosis, 37.3 ± 6.2Patients without cirrhosis, *n* = 73 Migliorati et al. 2006 \[[@CR66]\]Italy; BresciaSingle-centre, observational, retrospective analysisJan 2001--Dec 2002Patients ≥15 yrs hospitalised with discharge diagnosis of pneumonia or pneumonia-related disease, *n* = 148 (20 % nursing home residents)70.3 ± 17.3Chest X-ray confirmedSpain Sopena et al. 2007 \[[@CR28]\]Spain; BarcelonaSingle-centre, prospective, observational, cohort study1994--2004Adult patients hospitalised with community-acquired Legionnaires' disease, *n* = 251; 138 sporadic cases; 113 outbreak casesSporadic cases, 56.6 ± 15.5Laboratory evidence of acute infection with *L. pneumophila*Outbreak cases, 59.5 ± 16.6 Sopena et al. 2007 \[[@CR29]\]Spain; BarcelonaSingle-centre, retrospective, observational, cohort study1994--2004Patients hospitalised with CAP due to *L. pneumophila*, *n* = 158; 104 \<65 yrs; 54 ≥65 yrs\<65, 65.9 % of cohortLaboratory evidence of infection with *L. pneumophila*≥65, 34.1 %≥70, 13.9 %≥85, 1.9 % Garcia-Vidal et al. 2009 \[[@CR48]\]Spain; BarcelonaSingle-centre, prospective, observational cohort study1 Jan 1995--31 Dec 2005Patients hospitalised with CAP, *n* = 1,556; 146 with recurrent CAP (≥2 episodes of CAP in 3 yrs with asymptomatic period ≥1 month); 1,410 with non-recurrent CAPRecurrent CAP, 70.96 ± 13.824Clinical symptoms, chest X-ray confirmed and microbiological dataNon-recurrent CAP, 65.03 ± 16.573 Falguera et al. 2009 \[[@CR39]\]Spain; CataloniaTwo-centre, prospective, observational cohort studyJan 1995--Dec 2005Patients ≥18 yrs hospitalised with CAP, *n* = 3,272; 61 with Gram-negative infections; 3,211 with non-Gram-negative infections64 \[range 18--100\]Clinical symptoms, chest X-ray confirmed and microbiological dataGram-negative infections, 69Non-Gram-negative infections, 63 Ruiz et al. 2010 \[[@CR31]\]Spain; Basque countrySingle-centre, prospective, observational, cohort studyJan 1995--Dec 2007Adults hospitalised with bacteraemic CAP due to Gram-negative bacteria, *n* = 5172.9 ± 11.3Clinical symptoms, chest X-ray confirmed Viasus et al. 2011 \[[@CR46]\]Spain; BarcelonaSingle-centre, prospective, observational, cohort study13 Feb 1995--31 Dec 2008Patients with and without cirrhosis, hospitalised with CAP, *n* = 3,420; 90 with cirrhosis; 3,330 with no cirrhosisCirrhosis, 61.8 ± 13.0Chest X-ray and clinical symptomsNo cirrhosis, 66.8 ± 16.9 Viasus et al. 2011 \[[@CR50]\]Spain; BarcelonaSingle-centre, prospective, observational, cohort study13 Feb 1995--30 April 2010Adult patients with and without chronic renal disease, hospitalised with CAP, *n* = 3,800; 203 with renal disease (8.6 % nursing home residents); 3,597 with no renal disease (8.1 % nursing home residents)Renal disease, median 77 \[IQR 67--84\]Chest X-ray, clinical symptoms and microbiological dataNo renal disease, median 70 \[IQR 56--79\] de Roux et al. 2006 \[[@CR45]\]Spain; BarcelonaSingle-centre, prospective, observational cohort studyOct 1996--Nov 2001Patients hospitalised with CAP, classified according to alcohol abuse statusCurrent alcohol abuse, 58 ± 14Clinical symptoms, chest X-ray confirmed and microbiological dataCurrent, *n* = 128Former alcohol abuse, 71 ± 11Former, *n* = 54No alcohol abuse, 68 ± 19None, *n* = 1,165 Gutiérrez et al. 2005 \[[@CR40]\]Spain; AlicanteSingle-centre, prospective, observational, cohort study15 Oct 1999--14 Oct 2001Patients ≥15 yrs with CAP, *n* = 49356.6 \[range 15--94\]Clinical symptoms, chest X-ray confirmed and microbiological data Curran et al. 2008 \[[@CR34]\]Spain; BarcelonaSingle-centre, prospective, observational cohort studyJan 2000--Dec 2005HIV patients ≥18 yrs hospitalised with bacterial pneumonia, *n* = 161; 186 episodes39.7 ± 7.8Clinical symptoms, chest X-ray confirmed and response to antibacterial therapy Pérez-Sola et al. 2011 \[[@CR67]\]Spain; nationalMulticentre, prospective, observational, cohort studyFeb 2000--Jan 2006Patients with rheumatic diseases treated with TNF antagonists, *n* = 6,969; 101 with pneumonia50 ± 14CDC criteria Carratalà et al. 2007 \[[@CR43]\]Spain; BarcelonaSingle-centre, prospective, observational study1 Jan 2001--31 Dec 2004Adult patients with CAP requiring hospitalisation, *n* = 60163.7 ± 17.1Chest X-ray confirmed Cabre et al. 2010 \[[@CR25]\]Spain; MataróSingle-centre, prospective, observational studyJan 2001--Aug 2005Patients ≥70 yrs with CAP requiring hospitalisation, *n* = 134 (32 % nursing home residents)84.51 ± 6.8Chest X-ray confirmed Cillóniz et al. 2012 \[[@CR44]\]Spain; BarcelonaSingle-centre, prospective, observational cohort study2001--2009Adult patients hospitalised with pneumococcal pneumonia, *n* = 62663.6 ± 18.9Clinical symptoms, chest X-ray confirmed and microbiological data46 % ≤65 yrs Vila-Corcoles et al. 2009 \[[@CR26]\]Spain; TarragonaMulticentre, prospective, observational, population-based, cohort study1 Jan 2002--30 April 2005Community-dwelling individuals ≥65 yrs, *n* = 11,24165--74, 55.2 % of cohortChest X-ray and clinical symptoms75--84, 34.3 %≥85, 10.5 % Cillóniz et al. 2011 \[[@CR22]\]Spain; BarcelonaSingle-centre, prospective, observational cohort studyJan 2003--Dec 2010Patients with CAP admitted to ICU, *n* = 36263.4 ± 16.5Chest X-ray confirmed Molinos et al. 2009 \[[@CR38]\]Spain; AsturiasMulticentre, prospective, observational studyApril 2003--April 2004Patients hospitalised with CAP, *n* = 710; 244 with COPD; 466 no COPD (5 % nursing home residents in both groups)Overall, 67.14 \[95 % CI 65.9--68.4\]Clinical symptoms, chest X-ray confirmed and microbiological dataWith COPD, 73.7 \[95 % CI 72.5--74.9\]No COPD, 63.6 \[95 % CI 61.8--65.4\] Liapikou et al. 2012 \[[@CR42]\]Spain; BarcelonaSingle-centre, prospective, observational cohort study2004--2008Adult patients hospitalised with CAP, *n* = 1,379; 212 with COPD (5.7 % nursing home residents); 1,167 no COPD (10.2 % nursing home residents)Overall, 70 ± 17Clinical symptoms, chest X-ray confirmed and microbiological dataCOPD, 73.4 ± 8.8No COPD, 69.4 ± 17.9 Almirall et al. 2013 \[[@CR24]\]Spain; MataróSingle-centre, prospective, observational, case--control studyFeb 2008--Feb 2010Patients ≥70 yrs with CAP requiring hospitalisationCases, mean ± SEM 81.22 ± 0.77Chest X-ray confirmed and bacteriological identificationCases, *n* = 36Controls, mean ± SEM 81.21 ± 0.53Controls, *n* = 72 Giannella et al. 2012 \[[@CR49]\]Spain; nationalMulticentre, prospective, observational cohort studyJan and June 2010 (1 week in each month)Patients ≥16 yrs treated for CAP in the internal medicine department, *n* = 591Median 77 \[IQR 65--84\]Clinical symptoms, chest X-ray confirmedUK Bewick et al. 2012 \[[@CR68]\]UK; NottinghamTwo-centre, prospective, observational cohort studySept 2008--Sept 2010Patients ≥16 yrs hospitalised with CAP, *n* = 920 (5.5 % nursing home residents); 366 with pneumococcal pneumonia (6.8 % nursing home residents)Median 71.7 \[IQR 57.8--80.8\]Chest X-ray confirmed*CAP* community-acquired pneumonia; *CAPNETZ* Competence Network for Community-Acquired Pneumonia; *CDC* Centers for Disease Control and Prevention; *COPD* chronic obstructive pulmonary disease; *EB* Enterobacteriaceae; *GP* general practitioner; *HIV* human immunodeficiency virus; *ICU* intensive care unit; *IQR* interquartile range; *LRTI* lower respiratory tract infection; *PA Pseudomonas aeruginosa*; *SD* standard deviation; *SEM* standard error of the mean; *TNF* tumour necrosis factor; *yrs* years^a^Ten patients in this study were aged ≤14 yrs^b^This paper refers to patients with cirrhosis as 'Cases' and those without cirrhosis as 'Controls'. However, there is no evidence of any matching of 'cases' and 'controls'

The majority of studies included adults of all ages, but three studies considered only elderly patients (age ≥65 years) \[[@CR24]--[@CR26]\]. Additionally, most of the studies considered pneumonia of any aetiology, but six were performed in patients with pneumonia due to *L. pneumophila* (*n* = 3) \[[@CR27]--[@CR29]\], *Haemophilus influenzae* (*n* = 1) \[[@CR30]\], Gram-negative bacteria (*n* = 1) \[[@CR31]\], or *Enterobacteriaceae* or *P. aeruginosa* (*n* = 1) \[[@CR32]\]. Six studies were conducted in specific populations: five studies in patients with human immunodeficiency virus (HIV) \[[@CR33]--[@CR37]\] and one study in patients with chronic obstructive pulmonary disease (COPD) \[[@CR38]\].

Pathogens identified in patients with CAP {#Sec5}
-----------------------------------------

The aetiology of CAP was investigated in 25 observational studies in Denmark (*n* = 1), France (*n* = 2), Germany (*n* = 2), Italy (*n* = 2), Spain (*n* = 17) and the UK (*n* = 1). Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"} summarise these data to show the most common microbiological techniques, the overall frequency of isolation of pathogens and the frequency of isolation of pathogens specifically in HIV and COPD study cohorts. Full details of the microbiological techniques used and the pathogens isolated in each study are included in Supplementary Table [1](#MOESM1){ref-type="media"}.Table 2Microbiological techniques/samples used for the isolation of pathogens in patients with CAPMicrobiological technique/sampleNumber of studies using technique, *n* (%)ReferencesBlood culture22 (100)\[[@CR22]--[@CR24], [@CR26], [@CR31], [@CR34]--[@CR43], [@CR45], [@CR46], [@CR48]--[@CR50], [@CR65], [@CR68]\]Sputum culture20 (91)\[[@CR22]--[@CR24], [@CR26], [@CR34], [@CR36]--[@CR43], [@CR45], [@CR46], [@CR48]--[@CR50], [@CR65], [@CR68]\]Urine antigen test^a^19 (86)\[[@CR22]--[@CR24], [@CR26], [@CR31], [@CR34], [@CR36], [@CR38]--[@CR43], [@CR45], [@CR46], [@CR48]--[@CR50], [@CR68]\]Blood serology^b^15 (68)\[[@CR22], [@CR26], [@CR36], [@CR38]--[@CR43], [@CR45], [@CR46], [@CR48]--[@CR50], [@CR68]\]Pleural fluid10 (45)\[[@CR22]--[@CR24], [@CR34], [@CR38]--[@CR40], [@CR42], [@CR45], [@CR50]\]Tracheobronchial aspirate7 (32)\[[@CR22]--[@CR24], [@CR38], [@CR42], [@CR45], [@CR49]\]Bronchoalveolar lavage6 (27)\[[@CR22], [@CR23], [@CR37], [@CR45], [@CR49], [@CR68]\]Transthoracic needle aspirate4 (18)\[[@CR23], [@CR39], [@CR45], [@CR49]\]Normally sterile fluid culture3 (14)\[[@CR43], [@CR46], [@CR48]\]Nasopharyngeal swab3 (14)\[[@CR22], [@CR41], [@CR49]\]Sublingual smear1 (5)\[[@CR24]\]*CAP* community-acquired pneumonia; *n* number of studies using the given technique of the 22 studies reporting the microbiological techniques used for the isolation of pathogens in patients with CAP^a^For the detection of *Streptococcus pneumoniae* and *Legionella pneumophila*^b^For the detection of antibodies against specific pathogens or groups of pathogens, including *Legionella pneumophila*, *Chlamydophila pneumoniae*, *Coxiella burnetii*, *Mycoplasma pneumoniae*, *Chlamydophila psittaci*, *Chlamydia trachomatis* and respiratory virusesTable 3Patients with CAP and episodes of CAP with a pathogen identifiedAetiologyPatients with pathogen identified^a^Episodes with pathogen identified^a^ReferencesCohorts (*n*)^b^Studies (*n*)Range (%)Cohorts (*n*)^b^Studies (*n*)Range (%)Gram-positive bacteria  *Streptococcus pneumoniae*511912.0--85.0653.2--19.2\[[@CR22]--[@CR26], [@CR33]--[@CR43], [@CR45], [@CR46], [@CR48]--[@CR50], [@CR65], [@CR67], [@CR68]\]  *Staphylococcus aureus*39120.8--20.0223.3--6.5\[[@CR22], [@CR23], [@CR26], [@CR33], [@CR36], [@CR38], [@CR40]--[@CR42], [@CR46], [@CR49], [@CR50], [@CR65], [@CR67]\]  *Streptococcus viridans*111.7113.3\[[@CR22], [@CR36]\]Gram-negative bacteria Gram-negative enteric bacilli^c^39100.6--42.9321.7--7.8\[[@CR22], [@CR23], [@CR25], [@CR34], [@CR37], [@CR40], [@CR41], [@CR45], [@CR46], [@CR48]--[@CR50]\]  *Haemophilus influenzae*45151.1--29.4653.2--19.2\[[@CR22], [@CR23], [@CR25], [@CR26], [@CR33]--[@CR43], [@CR45], [@CR46], [@CR48]--[@CR50], [@CR65]\]  *Pseudomonas aeruginosa*14100.9--16.8225.9--6.7\[[@CR22], [@CR24], [@CR26], [@CR34], [@CR36], [@CR38], [@CR41]--[@CR43], [@CR45], [@CR49], [@CR67]\]  *Pseudomonas* species^d^1910.2--3.21119.4\[[@CR33], [@CR41]\]  *Klebsiella pneumoniae*550.3--5.0113.3\[[@CR24], [@CR26], [@CR36], [@CR38], [@CR42], [@CR43]\]  *Moraxella catarrhalis*2850.3--2.300--\[[@CR26], [@CR40]--[@CR42], [@CR46]\]  *Serratia marcescens*112.3113.3\[[@CR26], [@CR36]\]  *Escherichia coli*530.6--2.1116.7\[[@CR36], [@CR38], [@CR42], [@CR43]\]Atypical bacteria  *Mycoplasma pneumoniae*39100.7--61.300--\[[@CR22], [@CR23], [@CR38]--[@CR43], [@CR45], [@CR65]\]  *Legionella pneumophila*19121.7--20.1543.2--15.1\[[@CR22], [@CR25], [@CR26], [@CR34]--[@CR36], [@CR38]--[@CR40], [@CR42], [@CR43], [@CR45], [@CR46], [@CR48]--[@CR50]\]  *Legionella* species^e^2735.4--20.000--\[[@CR23], [@CR41], [@CR67]\]  *Chlamydophila pneumoniae*2990.1--9.900--\[[@CR22], [@CR23], [@CR26], [@CR38], [@CR39], [@CR41]--[@CR43], [@CR45]\]  *Coxiella burnetii*960.8--3.400--\[[@CR22], [@CR26], [@CR38], [@CR40], [@CR43], [@CR45]\]Virus38101.4--28.6110.7\[[@CR22], [@CR23], [@CR38], [@CR40]--[@CR42], [@CR45], [@CR46], [@CR48], [@CR49], [@CR65]\]*CAP* community-acquired pneumoniaPathogens only reported in one cohort in one study were excluded^a^Percentages are based on the number of patients/episodes in which pathogens were identified and data were available^b^For studies that only reported data separately for each cohort, all cohorts were included; for studies that reported data for the overall study population, the summary data were used. Studies performed in patients with pneumonia due to a specific pathogen were excluded^c^For studies \[[@CR22], [@CR23], [@CR25], [@CR34], [@CR37], [@CR40], [@CR41], [@CR45], [@CR46], [@CR48]--[@CR50]\], Gram-negative enteric bacilli were grouped together and individual pathogens in this group were not reported separately^d^For studies \[[@CR33], [@CR41]\], *Pseudomonas* species were not reported separately and, therefore, could include *P. aeruginosa*^e^For studies \[[@CR23], [@CR41], [@CR67]\], *Legionella* species were not reported separately and, therefore, could include *L. pneumophila*Table 4Prevalence of pathogens identified in patients with CAP with HIV or COPDAetiologyHIVCOPDPatients with pathogen identified^a^Episodes with pathogen identified^a^ReferencesPatients with pathogen identified^a^ReferencesRange (%)Range (%)Range (%)COPDNo COPDGram-positive bacteria  *Streptococcus pneumoniae*57.8--81.842.9--71.4\[[@CR33]--[@CR37]\]37.5--66.326.9--57.0\[[@CR38], [@CR40], [@CR42]\]  *Staphylococcus aureus*6.53.3\[[@CR33], [@CR36]\]1.10.8--3.2\[[@CR38], [@CR40], [@CR42]\]Gram-negative bacteria Gram-negative enteric bacilli^b^7.87.1--42.9\[[@CR33], [@CR34]\]16.73.1\[[@CR40]\]  *Haemophilus influenzae*3.2--9.16.7--14.3\[[@CR33]--[@CR37]\]1.1--4.21.7--3.8\[[@CR38], [@CR40], [@CR42]\]  *Pseudomonas aeruginosa*5.96.7\[[@CR34], [@CR36]\]2.1--7.40.9\[[@CR38], [@CR42]\]  *Escherichia coli*--6.7\[[@CR36]\]1.1--2.61.1--1.3\[[@CR38], [@CR42]\]  *Klebsiella pneumoniae*--3.3\[[@CR36]\]1.10.9\[[@CR38], [@CR42]\]  *Moraxella catarrhalis*----2.10.4\[[@CR40], [@CR42]\]  *Mycoplasma pneumoniae*----2.1--4.23.4--23.1\[[@CR38], [@CR40], [@CR42]\]  *Legionella pneumophila*9.1--10.83.3\[[@CR34]--[@CR36]\]2.1--12.51.7--3.8\[[@CR38], [@CR40], [@CR42]\]  *Chlamydophila pneumoniae*----2.1--6.34.1--4.5\[[@CR38], [@CR40], [@CR42]\]  *Coxiella burnetii*----2.11.5--3.4\[[@CR38], [@CR40]\]Virus----4.2--13.72.8--12.5\[[@CR38], [@CR40], [@CR42]\]*CAP* community-acquired pneumonia; *COPD* chronic obstructive pulmonary disease; *HIV*, human immunodeficiency virus^a^Percentages are based on the number of patients/episodes in which pathogens were identified and data were available^b^For studies \[[@CR33], [@CR34], [@CR40]\], Gram-negative enteric bacilli were grouped together and individual pathogens in this group were not reported separately

Microbiological methodologies used to establish the aetiology of CAP were reported in 67 % of the studies (*n* = 22). These methodologies were similar across studies and included the assessment of blood, sputum, urine and pleural fluid samples and, less commonly, tracheobronchial, bronchoalveolar, transthoracic and nasopharyngeal samples. Blood cultures were performed in all 22 studies (Table [2](#Tab2){ref-type="table"}) and all but one study reported using at least two different techniques. Other frequently used techniques for the isolation of pathogens were sputum culture (91 % of studies), urine antigen tests (specifically for the detection of *S. pneumoniae* and *L. pneumophila*; 86 % of studies), serology, for the detection of antibodies against specific pathogens, including *L. pneumophila*, *Chlamydophila pneumoniae*, *Coxiella burnetii*, *Mycoplasma pneumoniae*, *Chlamydophila psittaci*, *Chlamydia trachomatis* and respiratory viruses (68 % of studies), and pleural fluid culture (45 % of studies).

The percentages of patients and episodes of CAP in which a pathogen was not identified were 26.7--87.3 % and 44.2--77.0 %, respectively. In patients in whom a pathogen was identified, *S. pneumoniae* was the most commonly isolated and was identified in 12.0--85.0 % of patients within 19 studies (Table [3](#Tab3){ref-type="table"}). Of the atypical bacteria, *M. pneumoniae* (up to 61.3 % of patients within ten studies), *L. pneumophila* (up to 20.1 % of patients within 12 studies) and *C. pneumoniae* (up to 9.9 % of patients within nine studies) were frequently identified in patients with CAP, whereas *C. burnetii* was isolated less frequently (up to 3.4 % of patients within six studies). Other pathogens isolated included *S. aureus* (up to 20.0 % of patients within 12 studies), *P. aeruginosa* (up to 16.8 % of patients within ten studies), *Klebsiella pneumoniae* (up to 5.0 % of patients within five studies) and *Acinetobacter baumannii* (isolated in 2.0 % of patients in one study that was performed in patients hospitalised with bacteraemic CAP due to Gram-negative bacteria \[[@CR31]\]). CAP of mixed aetiology was reported in four studies in 0.4--19.9 % of patients \[[@CR22], [@CR26], [@CR39], [@CR40]\].

For studies with data available stratified by age (\<65 years and/or ≥65 years) \[[@CR23]--[@CR26], [@CR40], [@CR41]\], the frequencies of pathogens were generally similar between age groups. However, *S. pneumoniae* (\<65 years: 20.9--28.0 %; ≥65 years: 19.9--85.0 %), *H. influenzae* (\<65 years: 4.1--6.4 %; ≥65 years: 2.9--29.4 %) and respiratory viruses (\<65 years: 4.6--7.7 %; ≥65 years: 7.8--18.6 %) appeared to be more frequently isolated in elderly patients aged ≥65 years, and *M. pneumoniae* appeared to be more frequently isolated in younger patients (\<65 years: 14.0--25.1 %; ≥65 years: 0.7--6.8 %).

Among the studies reporting on the aetiology of CAP in patients with HIV \[[@CR33]--[@CR37]\], the frequencies of isolated pathogens were similar to those found for the overall data. *S. pneumoniae* was the most commonly isolated pathogen (57.8--81.8 % of patients), and *H. influenzae* and *L. pneumophila* were also often identified (Table [4](#Tab4){ref-type="table"}).

The aetiology of CAP was similar in patients with and without COPD \[[@CR38], [@CR40], [@CR42]\], in whom *S. pneumoniae*, *H. influenzae*, *L. pneumophila*, *M. pneumoniae* and respiratory viruses were all commonly identified (Table [4](#Tab4){ref-type="table"}). In one study, *P. aeruginosa* was reported in a significantly higher percentage of patients with COPD than in those without COPD (7.4 % vs. 0.9 %; *p* \< 0.01) and *L. pneumophila* was found to be significantly lower in patients with COPD than in those without COPD (2.1 % vs. 7.8 %; *p* \< 0.05) \[[@CR42]\].

Antibiotic treatment in patients with CAP {#Sec6}
-----------------------------------------

The antibiotic treatment of patients with CAP was reported in 23 studies: France (*n* = 1), Germany (*n* = 3), Greece (*n* = 1), Italy (*n* = 4) and Spain (*n* = 14). Rates of antibiotic treatment with beta-lactams, macrolides and quinolones are summarised in Table [5](#Tab5){ref-type="table"}. Full details of the antibiotic therapies for each study are provided in Supplementary Table [2](#MOESM2){ref-type="media"}.Table 5Antibiotic treatment in adults with CAPAntibioticCohorts (*n*)^a^Studies (*n*)Patients treated with antibiotic^b^, range (%)ReferencesMonotherapy31716.0--94.7\[[@CR22], [@CR40], [@CR41], [@CR43], [@CR44], [@CR46], [@CR47]\] Beta-lactams3285.0--87.7\[[@CR22], [@CR37], [@CR38], [@CR40], [@CR41], [@CR43], [@CR44], [@CR47]\] Macrolides3060.3--47.7\[[@CR37], [@CR38], [@CR40], [@CR41], [@CR44], [@CR47]\] Quinolones3282.0--46.0\[[@CR22], [@CR37], [@CR38], [@CR40], [@CR41], [@CR43], [@CR44], [@CR47]\] Other2630.7--8.8\[[@CR40], [@CR41], [@CR43]\]Combination therapy3385.0--84.0\[[@CR22], [@CR37], [@CR40], [@CR41], [@CR43], [@CR44], [@CR46], [@CR47]\] Beta-lactam + macrolide1071.7--70.0\[[@CR22], [@CR38], [@CR40], [@CR43]--[@CR45], [@CR47]\] Beta-lactam + quinolone446.3--63.0\[[@CR22], [@CR43], [@CR44], [@CR47]\] Macrolide + quinolone220.9--1.0\[[@CR44], [@CR47]\] Other542.0--38.0\[[@CR38], [@CR43], [@CR44], [@CR47]\]*CAP* community-acquired pneumonia^a^For studies that only reported data separately for each cohort, all cohorts were included; for studies that reported data for the overall study population, the summary data were used. Studies performed in patients with pneumonia due to a specific pathogen were excluded^b^Percentages are based on patients with available data

The rates of antibiotic treatments in patients with CAP were available in 13 studies \[[@CR22], [@CR28], [@CR29], [@CR36]--[@CR38], [@CR40], [@CR41], [@CR43]--[@CR47]\]. The rate of monotherapy ranged from 16.0 to 94.7 % of patients and the rate of combination antibiotic therapy ranged from 5.0 to 84.0 % of patients (Table [5](#Tab5){ref-type="table"}). The rate of antibiotic monotherapy with beta-lactams was higher than that for macrolides and quinolones. In one study, younger patients (\<65 years) received fewer beta-lactams and more quinolones than older patients (≥65 years) (beta-lactams: 62.5 % vs. 81.3 %; quinolones: 28.2 % vs. 17.1 %, respectively), whereas macrolide use was similar between age groups (32.6 % vs. 31.4 %, respectively) \[[@CR41]\]. For combination therapy, the most common combinations were beta-lactams combined with macrolides or quinolones. We found that the rate of combination antibiotic therapy was higher in patients in an intensive care unit (ICU; 84.0 %) and other hospitalised patients (31.8--69.0 %) than in outpatients (5.0--29.9 %) (Table [6](#Tab6){ref-type="table"}). Three studies reported data on antibiotic treatment in populations with comorbidities (COPD \[[@CR38]\] and liver disease \[[@CR46]\]) or lifestyle risk factors for CAP (alcoholism \[[@CR45]\]). Antibiotic treatments did not differ according to the presence or absence of COPD, liver disease or alcoholism.Table 6Antibiotic treatment in adults with CAP stratified by ICU patients, hospitalised patients and outpatientsAntibioticICU patientsHospitalised patientsOutpatientsReferencesCohorts (*n*)^a^Patients treated with antibiotic^b^, range (%)Cohorts (*n*)^a^Patients treated with antibiotic^b^, range (%)Cohorts (*n*)^a^Patients treated with antibiotic^b^, range (%)Monotherapy116.01230.3--68.2970.1--94.7\[[@CR22], [@CR41], [@CR43]--[@CR47]\] Beta-lactams15.0138.0--87.7940.1--48.9\[[@CR22], [@CR27], [@CR37], [@CR38], [@CR41], [@CR43], [@CR45], [@CR47]\] Macrolides----120.3--47.7914.1--22.1\[[@CR22], [@CR27], [@CR37], [@CR38], [@CR41], [@CR45], [@CR47]\] Quinolones111.0132.0--46.0912.0--39.2\[[@CR22], [@CR37], [@CR38], [@CR41], [@CR43]--[@CR45], [@CR47]\] Other----90.7--3.685.1--8.8\[[@CR41], [@CR43], [@CR45]\]Combination therapy184.01431.8--69.095.0--29.9\[[@CR22], [@CR37], [@CR41], [@CR43]--[@CR47]\] Beta-lactam + macrolide121.071.7--70.010.9\[[@CR22], [@CR38], [@CR43]--[@CR47]\] Beta-lactam + quinolone163.0227.0--28.116.3\[[@CR22], [@CR43], [@CR44], [@CR47]\] Macrolide + quinolone----11.010.9\[[@CR44], [@CR47]\] Other----42.0--38.0111.4\[[@CR38], [@CR43], [@CR44], [@CR47]\]*CAP* community-acquired pneumonia; *ICU* intensive care unit^a^For studies that only reported data separately for each cohort, all cohorts were included; for studies that reported data for the overall study population, the summary data were used. Studies performed in patients with pneumonia due to a specific pathogen were excluded^b^Percentages are based on patients with available data

In the 14 studies that reported on appropriate versus inappropriate antibiotic therapy \[[@CR22], [@CR23], [@CR27]--[@CR31], [@CR43], [@CR44], [@CR46]--[@CR50]\], the majority of patients had received adequate initial antibiotic treatment. Inappropriate antibiotic therapy was reported in 0--39.0 % of patients \[[@CR22], [@CR23], [@CR27]--[@CR32], [@CR43], [@CR44], [@CR46], [@CR48]--[@CR50]\]. One study showed that patients with polymicrobial CAP were significantly more likely than those with monomicrobial CAP (*p* \< 0.001) to receive inappropriate antibiotic treatment (39.0 % vs. 10.0 %, respectively) \[[@CR22]\]. Furthermore, inappropriate antibiotic therapy was found to be an independent predictor of mortality (univariate analysis: OR 11.23 \[95 % CI 4.44--28.38\], *p* \< 0.001; multivariate analysis: adjusted OR 10.79 \[3.97--29.30\], *p* \< 0.001) in one study \[[@CR22]\].

The antibiotic resistance of pathogens responsible for CAP was described in four studies conducted in 1995--2008 \[[@CR46]\], 2001 \[[@CR45]\], 2001--2004 \[[@CR43]\], 2001--2009 \[[@CR44]\] and 2002 \[[@CR30]\]. Penicillin resistance of *S. pneumoniae* was reported in 14.9--25.7 % of patients with CAP and in 8.4--20.7 % of isolates. Erythromycin resistance of *S. pneumoniae* was observed in 12.0--21 % of patients with CAP and in 14.7--17.1 % of isolates. In the two studies reporting on the antibiotic resistance of *H. influenzae*, beta-lactamase production was reported in 9.7 % \[[@CR43]\] and 80.0 % \[[@CR30]\] of isolates.

Discussion {#Sec7}
==========

This review provides a comprehensive overview of the aetiology of CAP and its antibiotic treatment in patients in Western Europe and builds on knowledge from earlier reviews of the incidence and risk factors for CAP among adults in this region \[[@CR7]\], the burden of CAP in Europe \[[@CR1]\] and a meta-analysis on the incidence of CAP in Europe by Rozenbaum et al. \[[@CR12]\]. In addition, it provides important information to be taken into consideration in future updates to the European guidelines for the management of CAP.

Microbiological methodologies for the isolation of pathogens {#Sec8}
------------------------------------------------------------

The majority of studies were in patients hospitalised for CAP and, as may be expected, blood cultures were used for the isolation of pathogens. This is in line with current guidelines from the European Respiratory Society (ERS) and the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) for the management of lower respiratory tract infections, which recommend that two sets of blood cultures are performed in patients hospitalised for CAP \[[@CR18]\]. However, a study conducted between 2007 and 2011 in 14 countries in Europe found that blood cultures were performed in only 50 % of patients hospitalised with CAP \[[@CR51]\]. This is similar to findings from a further retrospective, observational study in Europe conducted between 2010 and 2011 and published after the cut-off date for our search, in which blood cultures were performed in 55 % of patients hospitalised with CAP, suggesting that implementation of the guidelines across Europe is still incomplete \[[@CR52]\]. It is also possible that some European hospitals have adopted the approach advocated within the most recent Infectious Diseases Society of America (IDSA)/American Thoracic Society (ATS) recommendations, which limit blood cultures to patients hospitalised in the ICU \[[@CR53]\].

It is important to note that there are limitations in the methodologies used to evaluate the aetiology of CAP; for example, it is difficult to obtain all types of samples in all patients and many patients have received antibiotic treatment prior to sampling. Further limitations include the difficulty in obtaining a reliable sputum sample in the early stages of CAP in non-COPD patients and the technical limitations of diagnostic tests, such as a lack of sensitivity, or the poor ability of patients to form antibodies. Such limitations can lead to inaccurate estimations of the prevalence of pathogens \[[@CR54]\]. Furthermore, there are often a substantial number of patients in which the aetiology of CAP cannot be identified. Therefore, the rates of isolated pathogens reported in studies could be under- or overestimated due to false-negative or false-positive results, or the inability to isolate a pathogen \[[@CR54]\].

Aetiology of CAP in Europe {#Sec9}
--------------------------

We found that *S. pneumoniae* was the most common pathogen isolated in patients with CAP in Europe across the studies included in our review. However, there was substantial variation in the incidence of this pathogen (12.0--85.0 % of patients), which is comparable with findings from Welte et al., which identified *S. pneumoniae* in 11.9--68.3 % of patients with CAP, and from the meta-analysis by Rozenbaum et al. on the incidence of CAP in Europe, which identified *S. pneumoniae* in 19.3 % of CAP episodes \[[@CR1], [@CR12]\].

Other frequently identified pathogens found to cause CAP across the included studies in our review were *H. influenzae*, Gram-negative enteric bacilli, respiratory viruses and *M. pneumoniae*. These pathogens were identified at rates similar to those found by Welte et al. \[[@CR1]\], with the exception of *M. pneumoniae*, which was higher in our review (61.3 % vs. 32.4 % of patients). The high level of *M. pneumoniae* in our review was influenced by one study in particular, which consistently identified high *M. pneumoniae* rates in the age cohorts studied, particularly the younger cohorts \[[@CR41]\]. A possible reason for these high rates of *M. pneumoniae* is the cyclical nature of *M. pneumoniae* outbreaks, which occur every 3--7 years; hence, the prevalence of this organism in a given study varies with the inclusion of such yearly epidemics. Secondly, the study methodology for isolating *M. pneumoniae* used polymerase chain reaction (PCR) from bronchoalveolar lavage and throat swab samples, which were available for almost all patients, as well as sputum samples, which were available in only approximately 40 % of patients. Therefore, the true denominator for calculating *M. pneumoniae* rates differed from that for other pathogens, which resulted in an overestimation of the *M. pneumoniae* rate by two-fold \[[@CR41]\].

We found that the multidrug-resistant pathogens accounted for ≤20.0 % of CAP and that, of these pathogens, *S. aureus* and *P. aeruginosa* were more frequently isolated than *K. pneumoniae* or *A. baumannii*, which were rarely identified as the cause of CAP. In a European study of pathogens in hospitalised patients with CAP, multidrug-resistant pathogens were the cause of CAP in 3.3--7.6 % of patients in which a pathogen could be identified, with methicillin-resistant *S. aureus* being the most common multidrug-resistant pathogen \[[@CR55]\]. The study also found that patients with CAP caused by multidrug-resistant pathogens typically presented with more severe pneumonia on admission to hospital and, correspondingly, multidrug-resistant pathogens were more prevalent among those patients admitted to an ICU than among those admitted to a general ward \[[@CR55]\]. Overall, multidrug-resistant pathogens do not appear to be a major cause of CAP in Europe, but the severity of CAP caused by multidrug-resistant pathogens highlights the importance of routine testing for these pathogens. Probabilistic scores, such as the Aliberti and Shorr scores, can be useful for predicting the presence of multidrug-resistant pathogens in hospitalised patients and could help physicians to prescribe appropriate treatments without overprescribing broad-spectrum antibiotics \[[@CR55]\].

The frequency of pneumonia of mixed aetiology varied across the four studies in which it was identified, from 0.4 to 19.9 % of patients. One important factor likely to contribute to this variation is the diagnostic methods used to identify pathogens. It is probable that a higher percentage of polymicrobial infections will be identified using newer molecular techniques. These techniques are also likely to contribute to an increase in the percentage of infections in which a causative pathogen can be identified, reducing underdiagnosis and increasing the accuracy of diagnoses, which will potentially lead to improvements in the accuracy of treatment.

Differences in the groupings of pathogens between studies (e.g. Gram-negative enteric bacilli ± *P. aeruginosa*) may have led to underestimations in the prevalence of some pathogens, such as *P. aeruginosa*. As for *S. pneumoniae*, we generally found large ranges in the frequency of pathogens isolated across studies. Differences in the isolation rates of pathogens between studies could be due to many factors, including the severity of CAP, healthcare settings (e.g. patients treated in the community versus in the ICU), populations studied (e.g. age, comorbidities, risk factors) and diagnostic tests used (e.g. traditional methods versus new technology). For example, in a meta-analysis of the prevalence of *S. pneumoniae* in Europe, *S. pneumoniae* was more likely to be detected in studies that used PCR assays compared with studies that used other diagnostics tests (OR 2.49 \[95 % CI 1.39--4.46\]) \[[@CR12]\]. To establish the aetiology of CAP in Europe more accurately, improvements are needed in the sensitivity and specificity of diagnostic tests used to isolate pathogens. Furthermore, a more standardised approach to the diagnostic tests used will make comparisons across different studies more valid.

When looking at the aetiology of CAP stratified by age, we found a trend for *S. pneumoniae*, *H. influenzae* and respiratory viruses to be more frequent in elderly patients aged ≥65 years, and *M. pneumoniae* to be more frequent in those aged \<65 years. Similar age-related trends have been observed previously in a study of the microbial aetiology of CAP in adults in Finland \[[@CR54]\], in which *S. pneumoniae* infections were more frequent in adults aged ≥60 years than in those aged \<60 years (48 % vs. 35 %, *p* = 0.04) and infections with *M. pneumoniae* were more frequent in individuals aged 15--44 years compared with older adults (24 % vs. 3 %, *p* \< 0.001). The study in Finland also found viruses to be the cause of CAP in a higher proportion of older adults than younger adults; however, this trend was not significant. No consistent age-related trend was observed for *H. influenzae* \[[@CR54]\]. A study of the microbial patterns of CAP in patients aged ≥65 years found that *S. pneumoniae* was the most frequent pathogen in all age groups over 65 years and that age did not influence the microbial cause of CAP \[[@CR6]\]. In patients with COPD, we found that the aetiology of CAP was similar to that in patients without this condition. This was also observed in patients with HIV (in those who were non-severely immunocompromised or receiving treatment), which is in line with the results from studies examining the impact of HIV on the clinical outcomes of CAP in the highly active antiretroviral therapy era. Non-severely immunocompromised patients with HIV have been shown to have similar clinical outcomes in terms of the time to clinical stability, length of hospital stay and mortality rate when compared with individuals without HIV \[[@CR56], [@CR57]\].

Antibiotic treatment in patients with CAP {#Sec10}
-----------------------------------------

Current ERS/ESCMID guidelines (2011 edition) for the treatment of CAP \[[@CR18]\] recommend one of the following for the treatment of CAP in hospitalised patients:Aminopenicillin ± macrolideAminopenicillin beta-lactamase inhibitor ± macrolideNon-antipseudomonal cephalosporin IIICefotaxime or ceftriaxone ± macrolideLevofloxacinMoxifloxacinPenicillin G ± macrolide

The ERS/ESCMID guidelines suggest that combination therapy should be restricted to patients with severe presentation of CAP, with combination therapy being the treatment of choice for patients with severe CAP being treated in the ICU \[[@CR18]\]. In these patients, non-antipseudomonal cephalosporin III plus a macrolide, or moxifloxacin or levofloxacin ± non-antipseudomonal cephalosporin III are recommended in those patients without risk factors for *P. aeruginosa*, whereas in patients with risk factors for *P. aeruginosa*, antipseudomonal cephalosporin, or acylureidopenicillin beta-lactamase inhibitor or carbapenem, plus ciprofloxacin or plus macrolide plus aminoglycoside is preferred. When a specific pathogen has been identified, antibiotic therapy can be targeted against that pathogen. For example, for CAP caused by *Legionella* species, respiratory quinolones are recommended \[[@CR18]\]. In our study, we found that beta-lactams and macrolides were more frequently prescribed than quinolones. This was not unexpected, as some treatment guidelines reserve quinolones for when initial empirical therapy has failed, or specifically for the treatment of CAP caused by *Legionella* species (which was identified in up to 20.1 % of patients in this review) \[[@CR58]\].

Many European countries have their own national guidelines for the treatment of CAP \[[@CR54], [@CR58]--[@CR63]\], which are derived from the European guidelines and take into account the local epidemiology and aetiology of CAP, as well as the national resistance rate against antibiotics, such as penicillins and macrolides. This means that, although some similarities exist and the European guidelines provide a good framework for guidance, there are variations in the antibiotic management of CAP throughout Europe, depending on the specific requirements of each country.

A limited amount of data regarding antibiotic resistance were reported in the studies included in this review. By contrast, Welte et al. found several studies with data on antibiotic resistance \[[@CR1]\], possibly due to the use of different literature search criteria (e.g. differences in the time periods reviewed, databases searched, search terms used and inclusion/exclusion criteria applied). Antibiotic resistance against *S. pneumoniae* is the main clinical concern, due to its dominance in the aetiology of CAP. We found that pneumococcal resistance against penicillin was slightly higher than might be expected (8.4--20.7 % of isolates \[[@CR44], [@CR46]\]) when compared with that reported in Europe by the European Antimicrobial Resistance Surveillance Network (EARS-Net) in 2011 (8.8 % of isolates non-susceptible and 2.3 % resistant) \[[@CR64]\]. However, this may be because all of the studies in this review reporting penicillin resistance were carried out in Spain, which has one of the highest levels of penicillin resistance of *S. pneumoniae* in Europe \[[@CR64]\]. Pneumococcal resistance against erythromycin was similar to that reported by the EARS-Net for macrolides (14.7--17.1 % of isolates \[[@CR43]--[@CR46]\] vs. 14.1 % of isolates) \[[@CR64]\]. The literature review by Welte et al. highlighted a trend for increased antibiotic resistance of CAP-related pathogens in Europe, including *S. pneumoniae*, which showed an increase in resistance to commonly prescribed antibiotics \[[@CR1]\]. Globalisation and developments in healthcare may contribute to the changing pattern of the aetiology and antibiotic resistance of CAP. Understanding these changes is essential to guide best practices in the antibiotic management of CAP and to safeguard against the failure of empiric antibiotic treatment. The implementation of global surveillance systems would provide a means for guidelines to be adapted more rapidly in response to such changes.

Strengths and limitations {#Sec11}
-------------------------

This literature review was based on a review of published data from Europe that aimed to capture as many studies as possible from the past 7 years. The main strength of this review is that many of the included publications were case--control studies performed with large numbers of patients drawn from registries or primary care databases, rather than small, single-centre studies, thus giving reassurance that they provide a good representation of CAP in European populations. However, this review also has some limitations. There was a lack of a well-defined diagnostic protocol in many of the studies and the percentage of patients or episodes of CAP in which a specific causative pathogen was not identified was high in some studies (26.7--87.3 % and 44.2--77.0 %, respectively). The majority of the included studies were based on patient populations in Spain (20 of 33 studies) and this could potentially limit the validity of extrapolating the data from this review to other European populations.

Conclusion {#Sec12}
==========

In conclusion, this review has highlighted that *Streptococcus pneumoniae* is the most common pathogen responsible for community-acquired pneumonia (CAP) in adults in Europe and that beta-lactams are the most frequently prescribed class of antibiotics for the treatment of CAP. Understanding the aetiology of CAP and the changing pattern of antibiotic resistance in Europe, together with an increased awareness of the risk factors for CAP, will help clinicians to identify those patients most at risk of developing CAP and provide guidance on the most appropriate treatment.
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